Nuveen LLC Takes Position in Taysha Gene Therapies, Inc. $TSHA

Nuveen LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 546,414 shares of the company's stock, valued at approximately $760,000. Nuveen LLC owned approximately 0.27% of Taysha Gene Therapies at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Octagon Capital Advisors LP lifted its position in shares of Taysha Gene Therapies by 128.6% during the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock worth $18,078,000 after buying an additional 5,877,778 shares during the period. Bank of America Corp DE raised its position in Taysha Gene Therapies by 1,178.9% in the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock valued at $2,959,000 after purchasing an additional 1,576,568 shares during the last quarter. DAFNA Capital Management LLC bought a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $904,000. Granahan Investment Management LLC raised its position in shares of Taysha Gene Therapies by 43.6% during the fourth quarter. Granahan Investment Management LLC now owns 1,636,381 shares of the company's stock worth $2,831,000 after acquiring an additional 496,482 shares during the last quarter. Finally, Rafferty Asset Management LLC bought a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $436,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock traded up $0.10 on Friday, hitting $3.36. The stock had a trading volume of 5,126,381 shares, compared to its average volume of 2,954,448. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $3.40. The business's 50 day moving average is $2.71 and its two-hundred day moving average is $2.24. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The stock has a market cap of $916.61 million, a price-to-earnings ratio of -9.88 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The firm had revenue of $1.99 million during the quarter, compared to analyst estimates of $1.61 million. Analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Analysts Set New Price Targets

TSHA has been the subject of a number of analyst reports. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Needham & Company LLC restated a "buy" rating and issued a $8.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, July 1st. Canaccord Genuity Group boosted their price target on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, June 3rd. Chardan Capital increased their price objective on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Finally, Bank of America initiated coverage on Taysha Gene Therapies in a research report on Friday, July 11th. They set a "buy" rating and a $8.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of "Buy" and a consensus target price of $8.29.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.